Gastro Esophageal Reflux Clinical Trial
Official title:
Transpyloric Feeding for Prevention of Micro-aspiration
Verified date | January 2024 |
Source | Nemours Children's Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
To determine the effect of transpyloric (TP) feeding on microaspiration and lung inflammation in ventilated preterm infants.
Status | Active, not recruiting |
Enrollment | 46 |
Est. completion date | December 15, 2024 |
Est. primary completion date | May 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Months to 12 Months |
Eligibility | Inclusion Criteria: - Preterm infants with birth weight <1500 grams - Requiring ventilatory support Exclusion Criteria: - Culture-proven sepsis - Ventilator associated pneumonia (VAP). |
Country | Name | City | State |
---|---|---|---|
United States | Thomas Jefferson University Hospital | Philadelphia | Pennsylvania |
United States | AI duPont Hospital for Children | Wilmington | Delaware |
Lead Sponsor | Collaborator |
---|---|
Nemours Children's Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tracheal aspirate pepsin A levels in ventilated preterm infants receiving transpyloric feeding and gastric feeding. | Difference in tracheal aspirate pepsin A levels in preterm ventilated infants receiving transpyloric feeding and gastric feeding. | 3-7 days | |
Secondary | Tracheal aspirate pepsin A levels in ventilated preterm infants before and after transpyloric feeding. | Change in tracheal aspirate pepsin A levels in preterm ventilated infants before and after transpyloric feeding. | 3-7 days | |
Secondary | Tracheal aspirate cytokines levels (TNF-a, IL-1ß, IL-6, IL-8, Ang2, HMGB1, MIF and IFN-gamma) in ventilated preterm infants receiving transpyloric feeding and gastric feeding. | Difference in tracheal aspirate cytokines levels (TNF-a, IL-1ß, IL-6, IL-8, Ang2, HMGB1, MIF and IFN-gamma) in preterm ventilated infants receiving transpyloric feeding and gastric feeding. | 3-7 days. | |
Secondary | Tracheal aspirate cytokines levels (TNF-a, IL-1ß, IL-6, IL-8, Ang2, HMGB1, MIF and IFN-gamma) in ventilated preterm infants before and after transpyloric feeding. | Change in tracheal aspirate cytokines levels (TNF-a, IL-1ß, IL-6, IL-8, Ang2, HMGB1, MIF and IFN-gamma) in preterm ventilated infants before and after transpyloric feeding. | 3-7 days | |
Secondary | Respiratory support in ventilated preterm infants receiving transpyloric feeding and gastric feeding. | Difference in respiratory severity score (FiO2 X mean airway pressure) in preterm ventilated infants receiving transpyloric feeding and gastric feeding. | 7-14 days | |
Secondary | Respiratory support in ventilated preterm infants before and transpyloric feeding. | Change in respiratory severity score (FiO2 X mean airway pressure) in preterm ventilated infants before and after transpyloric feeding. | 7-14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06025773 -
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
|
Phase 1 | |
Recruiting |
NCT06280664 -
Efficacy Of Hiatal Closure For GERD
|
||
Recruiting |
NCT05359965 -
Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF
|
N/A | |
Completed |
NCT04202692 -
Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment
|
N/A | |
Recruiting |
NCT06430047 -
Efficacy and Safety of EsoDuo®
|
Phase 4 | |
Completed |
NCT04268719 -
Near Focus NBI-Driven Artificial Intelligence for the Diagnosis of Gastro-Oesophageal Reflux Disease
|
||
Active, not recruiting |
NCT04614974 -
Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia
|
Phase 1/Phase 2 | |
Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
Recruiting |
NCT03868267 -
Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
|
||
Terminated |
NCT04028466 -
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features
|
Phase 4 | |
Active, not recruiting |
NCT05371717 -
Domiciliary Management of Dental Erosion in Patients With GERD With Biomimetic Hydroxyapatite
|
N/A | |
Recruiting |
NCT05066594 -
Observational Registry of Transoral Incisionless Fundoplication (TIF) for Gastroesophageal Reflux Disease (GERD)
|
||
Completed |
NCT03476265 -
Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility
|
N/A | |
Completed |
NCT03143608 -
GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery
|
N/A | |
Completed |
NCT04436159 -
Partial Versus Total Fundoplication in the Surgical Repair of Para-esophageal Hernia.
|
N/A | |
Completed |
NCT03258528 -
Effect of Right Lateral Position on Ventilated Preterm Neonates
|
N/A | |
Active, not recruiting |
NCT04500288 -
The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study
|
N/A | |
Completed |
NCT04262648 -
Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns
|
N/A | |
Recruiting |
NCT04846010 -
Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03835663 -
The Bacterial Composition of the Stomach in Reflux Disease
|